Long-lasting reduction in clonogenic potential of colorectal cancer cells by sequential treatments with 5-azanucleosides and topoisomerase inhibitors

BACKGROUND: The currently approved therapies fail in a substantial number of colorectal cancer (CRC) patients due to the molecular heterogeneity of CRC, hence new efficient drug combinations are urgently needed. Emerging data indicate that 5-azanucleosides are able to sensitize cancer cells to the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Pawlak, Alicja, Ziolo, Ewa, Fiedorowicz, Anna, Fidyt, Klaudyna, Strzadala, Leon, Kalas, Wojciech
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112712/
https://www.ncbi.nlm.nih.gov/pubmed/27852227
http://dx.doi.org/10.1186/s12885-016-2925-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112712/
https://www.ncbi.nlm.nih.gov/pubmed/27852227
http://dx.doi.org/10.1186/s12885-016-2925-6

Ejemplares similares